Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Our Fool likes the look of these stock market juggernauts for the chunky passive income they throw off, not to mention their ...
Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.